Table 4.
Subgroup analysis.
| Clinical Characteristics | With Replicative Intermediates (B19V-RNA+) | Without Replicative Intermediates (B19V-RNA−) |
|---|---|---|
| Number of patients, n (%) | 126 | 96 |
| Age, mean ± SD (years) | 48.1 ± 16.4 | 48.3 ± 13.2 |
| LVEF, mean baseline ± SD (%) | 45.5 ± 18.2 | 48.6 ± 19.1 a |
| LVEF, mean follow-up ± SD (%) | 52.0 ± 17.2 b | 56.8 ± 15.3 ab |
| LVEF recovery (%) | 38.0 | 52.0 a |
| LVEDD, mean baseline ± SD (mm) | 55.8 ± 9.5 | 56.2 ± 10.4 |
| LVEDD, mean follow-up ± SD (mm) | 58.1 ± 9.0 | 55.3 ± 10.2 a |
| LVESD, mean baseline ± SD (mm) | 41.4 ± 12.9 | 41.6 ± 14.7 |
| LVESD, mean follow-up ± SD (mm) | 44.9 ± 12.0 | 40.4 ± 14.0 |
| Medication, % | ||
| - β-blockers | 47.5 | 49.2 |
| - ACE inhibitors/ARB | 73.2 | 72.3 |
| - diuretic agents | 51.1 | 53.1 |
| Biopsy (inflammatory cell counts) | ||
| CD3+, mean ± SD (cells/mm2) | 10.3 ± 14 | 9.9 ± 21.3 |
| CD45R0+, mean ± SD (cells/mm2) | 28.5 ± 29.7 | 26.8 ± 72.5 |
| LFA-1+, mean ± SD (cells/mm2) | 23.6 ± 26.6 | 29.6 ± 118 |
| Mac-1+, mean ± SD (cells/mm2) | 43.1 ± 33.9 | 48.6 ± 123.3 |
Note: ACE inhibitor = angiotensin-converting-enzyme inhibitor; ARB = angiotensin receptor blocker; B19V = parvovirus B19; LVEDD = left ventricular end-diastolic diameter, LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; CD3 = t cells; CD45R0 = t memory cells; LFA-1 = Lymphocyte function-associated antigen 1; MAC-1 = Macrophage-1 antigen. The data are presented as mean + standard deviation (SD), as %, and as No. of subjects. a Significantly different; B19V-RNA+ vs. B19V-RNA−. b Significantly different; baseline vs. follow-up.